Targovax to present at DNB healthcare conference Targovax

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Targovax to present at DNB healthcare conference

Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present a corporate overview at the following conference:

DNB Nordic Healthcare conference Date: 15 December 2016 Participants: Øystein Soug (CEO) and Magnus Jäderberg (CMO) Presentation time: 09:30 CET Venue: DNB, Oslo

The presentation will be available to download at www.targovax.com following this event.

For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com

Media and IR enquires: Jan Petter Stiff - Crux Advisers (Norway) Phone: +47 995 13 891 Email: stiff@crux.no

Julia Phillips/Simon Conway - FTI Consulting (International) Phone: +44 20 3727 1000 Email: Targovax@fticonsulting.com

About Targovax

Arming the patient's immune system to fight cancer

Targovax is a clinical stage company focused on developing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

The Company's development pipeline has arisen from two novel proprietary platforms:

The first platform, ONCOS, uses oncolytic viruses, an emerging class of biological therapy. ONCOS exclusively uses an adenovirus that has been engineered to be a tumor-targeted immune activator. The platform has the potential to generate therapies with superior efficacy and safety compared to the first approved oncolytic virus therapy, Imlygic, recently launched by Amgen. We expect proof of concept data related to immune activation in tumor tissue in 2017 from the clinical trial of ONCOS-102 in combination with CPI in patients with refractory malignant melanoma.

The second platform, TG-Peptides, solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platform's therapeutic potential stems from its ability to enable a patient's immune system to identify and then destroy tumors bearing any RAS mutations.

The development pipeline has three novel therapeutic candidates in clinical development covering six indications and has already demonstrated promising safety and tolerability data and early signs of clinical response.

Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. Our portfolio of future opportunities comprises a number of early stage development candidates in addition to the three outlined above.

In July 2016, the Company listed its shares on Oslo Axess, securing funding for further development of the Company's ongoing and planned trials.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 37

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 113

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

SRM Entertainment Expands Horizon with Strategic Moves.

Updated Category News Views 238

SRM Entertainment's Strategic Growth Plans SRM Entertainment, Inc. (Nasdaq: SRM) is taking bold steps to enhance its market position and create long-term value for its shareholders. Despite receiving numerous inquiries from investors regarding potential capital raises, the company has confirmed no immediate plans to seek additional funding. This strategic decision aligns...

Continue Reading
SBA Communications Unveils Tax Reporting Details for 2024

Updated Category News Views 149

SBA Communications Corporation Announces 2024 Tax Reporting Insights SBA Communications Corporation (Nasdaq: SBAC) has shared important tax reporting information concerning its distributions for 2024. As stockholders prepare for their tax obligations, the company encourages them to seek advice from their personal tax advisors to ensure they understand their specific tax...

Continue Reading
electroCore Achieves Significant Milestone with New Patents

Updated Category News Views 157

electroCore Enhances Innovation Through New Patents electroCore, Inc. (NASDAQ: ECOR), a leading figure in the bioelectronic medicine and wellness space, has recently made headlines by receiving notifications for five new patents issued by the United States Patent and Trademark Office (USPTO). This expansion of its intellectual property portfolio not only underscores...

Continue Reading
Empowering Grassroots: A Great Idea’s New Microgrant Initiative

Updated Category News Views 252

Introducing the A Great Idealist Microgrant Program A Great Idea (AGI) has recently unveiled its A Great Idealist Microgrants program, designed to provide crucial financial support to grassroots organizers, community advocates, and innovative leaders across the nation. This initiative echoes AGI's commitment to uplift and empower those at the forefront of social change....

Continue Reading
Elevat and HydraForce Team Up for Game-Changing Solutions

Updated Category News Views 249

Dynamic Partnership Set to Transform OEM Offerings What’s brewing in the world of industrial machine intelligence? It’s more than a merger—it’s a strategic collaboration that’s about to shake things up. Elevat, that Seattle-based powerhouse known for its cutting-edge solutions, has joined forces with HydraForce, backed by Bosch, to roll out some impressive...

Continue Reading